AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2172351 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine (intradermal injection, 50 microliters, concentrations ranging from 3.3 x 10(‐4) to 3.3 x 10(‐9) mol/L)
Number of subjects: 20
Study 2172351 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukotrienes C4, D4, and E4 (intradermal injection, 50 microliters, concentrations ranging from 2 x 10(‐4) to 2 x 10(‐9) mol/L)
Number of subjects: 20
Study 2172351 — intervention group
Group type: COMPARATOR
Intervention: Histamine (intradermal injection, 50 microliters)
Number of subjects: 20
Study 373088 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg levamisole tablets, one tablet t.i.d. for 3 months, then one tablet t.i.d. on 2 consecutive days every week for the next 3 months
Number of subjects: 33
Study 373088 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg levamisole tablets
Number of subjects: 33
Study 373088 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 373088 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 33
Study 30288741 — intervention group
Group type: EXPERIMENTAL
Intervention: Oesophageal compression by 30 N paratracheal force (paratracheal group)
Number of subjects: 90
Study 30288741 — intervention group
Group type: EXPERIMENTAL
Intervention: Oesophageal compression by 30 N cricoid force (cricoid group)
Number of subjects: 90
Study 30288741 — intervention group
Group type: COMPARATOR
Intervention: No oesophageal compression (control group)
Number of subjects: 90
Study 28345814 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg once daily plus exenatide 2 mg once weekly
Number of subjects: 50
Study 28345814 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 26041602 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan 8 mg + Hydrochlorothiazide 6.25 mg (combination regimen)
Number of subjects: 206
Study 26041602 — intervention group
Group type: COMPARATOR
Intervention: Candesartan 12 mg (maximum dose regimen)
Number of subjects: 206
Study 25608547 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based comprehensive fall prevention program (balance exercises, elastic resistance exercises, prevention education), provided five times a week for 8 weeks, each session lasting 90 minutes.
Number of subjects: 57
Study 25608547 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided).
Number of subjects: 57
Study 21618678 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodixanol
Number of subjects: 12
Study 21618678 — intervention group
Group type: EXPERIMENTAL
Intervention: Ioxaglate
Number of subjects: 12
Study 21618678 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 12
Study 21618678 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulants (enoxaparin, unfractionated heparin, fondaparinux, bivalirudin)
Number of subjects: 12
Study 19731994 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac plus B vitamins (50 mg diclofenac + 50 mg thiamine + 50 mg pyridoxine + 1 mg cyanocobalamin)
Number of subjects: 372
Study 19731994 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac monotherapy (50 mg diclofenac)
Number of subjects: 372
Study 17963111 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-methylpyrazole (4-MP)
Number of subjects: 0
Study 17963111 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15480514 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI examination after radiotherapy
Number of subjects: 7
Study 15480514 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI examination
Number of subjects: 7
Study 11443205 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegvisomant (1 mg/kg)
Number of subjects: 12
Study 11443205 — intervention group
Group type: COMPARATOR
Intervention: Saline (0.5 mL)
Number of subjects: 12
Study 9522024 — intervention group
Group type: COMPARATOR
Intervention: Chloral hydrate (CH) 500 mg as drinking solution
Number of subjects: 18
Study 9522024 — intervention group
Group type: COMPARATOR
Intervention: Chloraldurat rot (CR) one capsule
Number of subjects: 18
Study 9522024 — intervention group
Group type: COMPARATOR
Intervention: Chloraldurat blau (CB) one capsule
Number of subjects: 18
Study 9522024 — intervention group
Group type: EXPERIMENTAL
Intervention: Reference drinking solution (150 ml)
Number of subjects: 18
Study 8019117 — intervention group
Group type: EXPERIMENTAL
Intervention: pH adjusted 0.75% bupivacaine
Number of subjects: 0
Study 8019117 — intervention group
Group type: COMPARATOR
Intervention: 50:50 mixture of 1% lignocaine and 0.5% bupivacaine with hyaluronidase
Number of subjects: 0
Study 3383574 — intervention group
Group type: EXPERIMENTAL
Intervention: NET:CHOL (norethisterone-cholesterol eutectic mixture)
Number of subjects: 5
Study 3383574 — intervention group
Group type: COMPARATOR
Intervention: NET:LAC (control formulation)
Number of subjects: 5
Study 3383574 — intervention group
Group type: COMPARATOR
Intervention: Dianor (commercial tablet)
Number of subjects: 5
Study 31340755 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadoxetic acid-enhanced MRI
Number of subjects: 128
Study 31340755 — intervention group
Group type: COMPARATOR
Intervention: Multidetector CT (MDCT)
Number of subjects: 128
Study 28974344 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifesaver
Number of subjects: 81
Study 28974344 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face (F2F) training
Number of subjects: 81
Study 28974344 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined group (Lifesaver + F2F)
Number of subjects: 81
Study 28974344 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 81
Study 26310670 — intervention group
Group type: EXPERIMENTAL
Intervention: AL‐8309B 1.0%
Number of subjects: 768
Study 26310670 — intervention group
Group type: EXPERIMENTAL
Intervention: AL‐8309B 1.75%
Number of subjects: 768
Study 26310670 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 768
Study 23850610 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) administration of LIPO-4 vaccine (0.5 ml, 500 μg of each lipopeptide)
Number of subjects: 68
Study 23850610 — intervention group
Group type: COMPARATOR
Intervention: Intradermal (ID) administration of LIPO-4 vaccine (0.1 ml, 100 μg of each lipopeptide)
Number of subjects: 68
Study 23850610 — intervention group
Group type: COMPARATOR
Intervention: Intradermal (ID) administration of LIPO-4 vaccine
Number of subjects: 68
Study 23850610 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) administration of LIPO-4 vaccine
Number of subjects: 68
Study 21498394 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine
Number of subjects: 568
Study 21498394 — intervention group
Group type: EXPERIMENTAL
Intervention: Haplotypes
Number of subjects: 568
Study 19884541 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal methotrexate
Number of subjects: 171
Study 19884541 — intervention group
Group type: COMPARATOR
Intervention: Triple intrathecal therapy (methotrexate with cytarabine and hydrocortisone)
Number of subjects: 171
Study 17325684 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone approach
Number of subjects: 96
Study 17325684 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinic approach
Number of subjects: 96
Study 17325684 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 96
Study 14702493 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 0.3%/dexamethasone 0.1% otic suspension, 4 drops twice daily for 7 days
Number of subjects: 599
Study 14702493 — intervention group
Group type: COMPARATOR
Intervention: Ofloxacin 0.3% otic solution, 5 drops twice daily for 10 days
Number of subjects: 599
Study 14702493 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin/dexamethasone
Number of subjects: 599
Study 14702493 — intervention group
Group type: COMPARATOR
Intervention: Ofloxacin
Number of subjects: 599
Study 11381675 — intervention group
Group type: EXPERIMENTAL
Intervention: E5880 (300 micrograms or 1200 micrograms twice daily) administered intravenously for 14 days
Number of subjects: 71
Study 9268994 — intervention group
Group type: EXPERIMENTAL
Intervention: Pars plana vitrectomy with identified risk factors
Number of subjects: 42
Study 9268994 — intervention group
Group type: COMPARATOR
Intervention: Control group (age- and sex-matched subjects)
Number of subjects: 42
Study 8094828 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone (IVMP) 500 mg daily for 5 days
Number of subjects: 242
Study 8094828 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 242
Study 8094828 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone (IVMP)
Number of subjects: 242
Study 3531936 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 or 2 mg pure porcine relaxin
Number of subjects: 71
Study 3531936 — intervention group
Group type: COMPARATOR
Intervention: Placebo (distilled water)
Number of subjects: 71
Study 3531936 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg pure porcine relaxin
Number of subjects: 71
Study 3531936 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracervical application of relaxin
Number of subjects: 71
Study 31131671 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial Spin Labeling (ASL) imaging at 48 hours, 7 days, and 30 days after ICH onset
Number of subjects: 20
Study 31131671 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline systolic blood pressure (SBP) measurements
Number of subjects: 20
Study 31131671 — intervention group
Group type: EXPERIMENTAL
Intervention: Perilesional rCBF measurement
Number of subjects: 20
Study 30093093 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D laparoscopic tasks with eye exercises
Number of subjects: 24
Study 30093093 — intervention group
Group type: COMPARATOR
Intervention: 3D laparoscopic tasks without eye exercises
Number of subjects: 24
Study 30093093 — intervention group
Group type: COMPARATOR
Intervention: 2D laparoscopic tasks
Number of subjects: 24
Study 27793204 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g of intravenously administered ferric carboxymaltose
Number of subjects: 0
Study 27793204 — intervention group
Group type: COMPARATOR
Intervention: 10 g of iron fumarate supplements at one to two daily doses of 100 mg each
Number of subjects: 0
Study 24690309 — intervention group
Group type: EXPERIMENTAL
Intervention: Diary self-monitoring of blood glucose (SMBG) records
Number of subjects: 95
Study 24690309 — intervention group
Group type: COMPARATOR
Intervention: Meter self-monitoring of blood glucose (SMBG) records
Number of subjects: 95
Study 24690309 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall monitoring process
Number of subjects: 95
Study 21955037 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial-based thought record (TBTR)
Number of subjects: 36
Study 21955037 — intervention group
Group type: COMPARATOR
Intervention: Conventional cognitive therapy (CCT)
Number of subjects: 36
Study 20952764 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (NTX)
Number of subjects: 0
Study 20952764 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate (ACAMP)
Number of subjects: 0
Study 20952764 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17346288 — intervention group
Group type: EXPERIMENTAL
Intervention: EIMD (exercise-induced muscle damage) group jumped 100 times from a 35 cm bench
Number of subjects: 30
Study 17346288 — intervention group
Group type: COMPARATOR
Intervention: Control group (no muscle-damaging exercise)
Number of subjects: 30
Study 17346288 — intervention group
Group type: EXPERIMENTAL
Intervention: EIMD group
Number of subjects: 30
Study 15766302 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly oral morphine
Number of subjects: 23
Study 15766302 — intervention group
Group type: COMPARATOR
Intervention: Lorazepam
Number of subjects: 23
Study 15766302 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 11982838 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% lidocaine
Number of subjects: 15
Study 11982838 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline
Number of subjects: 15
Study 10218756 — intervention group
Group type: EXPERIMENTAL
Intervention: Trace elements (zinc sulfate and selenium sulfide)
Number of subjects: 725
Study 10218756 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamins (beta carotene, ascorbic acid, and vitamin E)
Number of subjects: 725
Study 10218756 — intervention group
Group type: EXPERIMENTAL
Intervention: Trace elements (zinc and selenium sulfide)
Number of subjects: 725
Study 10218756 — intervention group
Group type: EXPERIMENTAL
Intervention: Trace elements and vitamins
Number of subjects: 725
Study 10218756 — intervention group
Group type: COMPARATOR
Intervention: All groups (including control)
Number of subjects: 725
Study 7599570 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron
Number of subjects: 30
Study 7599570 — intervention group
Group type: COMPARATOR
Intervention: Comparator (metoclopramide, dexamethasone phosphate, and lorazepam)
Number of subjects: 30
Study 2096775 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiotepa instillations in the bladder
Number of subjects: 155
Study 2096775 — intervention group
Group type: COMPARATOR
Intervention: Adriamycin instillations in the bladder
Number of subjects: 155
Study 2096775 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin instillations in the bladder
Number of subjects: 155
Study 630810 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracellular volume expansion (ECVE) during water diuresis
Number of subjects: 0
Study 630810 — intervention group
Group type: COMPARATOR
Intervention: Water diuresis alone
Number of subjects: 0
Study 31182147 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-regulation-based e- and m-health intervention 'MyPlan 2.0' with action planning, coping planning, and self-monitoring techniques.
Number of subjects: 0
Study 31182147 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified what intervention they receive).
Number of subjects: 0
Study 28822563 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (placebo controlled trial)
Number of subjects: 147
Study 28822563 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 147
Study 25736397 — intervention group
Group type: EXPERIMENTAL
Intervention: udenafil 50mg
Number of subjects: 346
Study 25736397 — intervention group
Group type: EXPERIMENTAL
Intervention: udenafil 75mg
Number of subjects: 346
Study 25736397 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 346
Study 22842285 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic Rectilinear (BR) waveform
Number of subjects: 199
Study 22842285 — intervention group
Group type: COMPARATOR
Intervention: Biphasic Truncated Exponential (BTE) waveform
Number of subjects: 199
Study 21372264 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive T2DM patients
Number of subjects: 3738
Study 21372264 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure (BP)
Number of subjects: 3738
Study 21372264 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent factors associated with albuminuria
Number of subjects: 3738
Study 21372264 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent risk factors for renal insufficiency (RI)
Number of subjects: 3738
Study 19926048 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.50 mg/kg enoxaparin
Number of subjects: 3528
Study 19926048 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 mg/kg enoxaparin
Number of subjects: 3528
Study 19926048 — intervention group
Group type: COMPARATOR
Intervention: UFH (unfractionated heparin)
Number of subjects: 3528
Study 19926048 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonfatal myocardial infarction and/or urgent target vessel revascularization
Number of subjects: 3528
Study 19926048 — intervention group
Group type: EXPERIMENTAL
Intervention: Major bleeding within 48 h
Number of subjects: 3528
Study 16427543 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IP) with 10 minutes of portal triad clamping and 10 minutes of reperfusion
Number of subjects: 60
Study 16427543 — intervention group
Group type: COMPARATOR
Intervention: Control group without ischemic preconditioning
Number of subjects: 60
Study 16427543 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IP)
Number of subjects: 60
Study 14657039 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein supplement (8 g carbohydrate, 10 g protein, 3 g fat)
Number of subjects: 387
Study 14657039 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 g carbohydrate, 0 g protein, 0 g fat)
Number of subjects: 387
Study 14657039 — intervention group
Group type: COMPARATOR
Intervention: Control (8 g carbohydrate, 0 g protein, 3 g fat)
Number of subjects: 387
Study 11785111 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative radiotherapy (IORT) combined with preoperative irradiation and radical surgery
Number of subjects: 0
Study 9212142 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane (0.4‐1.2 vol%)
Number of subjects: 40
Study 9212142 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (3‐5 mg x kg(‐1) x h(‐1) intravenously)
Number of subjects: 40
Study 9212142 — intervention group
Group type: COMPARATOR
Intervention: Both isoflurane and propofol
Number of subjects: 40
Study 9212142 — intervention group
Group type: EXPERIMENTAL
Intervention: Threshold value of Nb
Number of subjects: 40
Study 7963201 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevention team intervention (flowsheet used, patient education offered, staff tasks redefined)
Number of subjects: 1202
Study 7963201 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education intervention
Number of subjects: 1202
Study 7963201 — intervention group
Group type: COMPARATOR
Intervention: Control group (no further intervention)
Number of subjects: 1202
Study 7963201 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevention team intervention
Number of subjects: 1202
Study 3671250 — intervention group
Group type: EXPERIMENTAL
Intervention: nifedipine (up to 60 mg/day)
Number of subjects: 93
Study 3671250 — intervention group
Group type: EXPERIMENTAL
Intervention: prazosin (up to 20 mg/day)
Number of subjects: 93
Study 3671250 — intervention group
Group type: EXPERIMENTAL
Intervention: hydralazine (up to 200 mg/day)
Number of subjects: 93
Study 30922878 — intervention group
Group type: EXPERIMENTAL
Intervention: ABCP (atezolizumab plus bevacizumab plus carboplatin plus paclitaxel)
Number of subjects: 1202
Study 30922878 — intervention group
Group type: COMPARATOR
Intervention: BCP (bevacizumab plus carboplatin plus paclitaxel)
Number of subjects: 1202
Study 30922878 — intervention group
Group type: EXPERIMENTAL
Intervention: ABCP
Number of subjects: 1202
Study 30922878 — intervention group
Group type: EXPERIMENTAL
Intervention: ACP (atezolizumab plus carboplatin plus paclitaxel)
Number of subjects: 1202
Study 30922878 — intervention group
Group type: EXPERIMENTAL
Intervention: ACP
Number of subjects: 1202
Study 30922878 — intervention group
Group type: COMPARATOR
Intervention: BCP
Number of subjects: 1202
Study 30273216 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse intervention the day before surgery and admission in the ICU
Number of subjects: 40
Study 30273216 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control group)
Number of subjects: 40
Study 26825788 — intervention group
Group type: EXPERIMENTAL
Intervention: XLIF
Number of subjects: 55
Study 26825788 — intervention group
Group type: COMPARATOR
Intervention: MIS TLIF
Number of subjects: 55
Study 24641328 — intervention group
Group type: EXPERIMENTAL
Intervention: -6° head-down bed rest for 60 days
Number of subjects: 49
Study 24641328 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypobaric hypoxia at Concordia station
Number of subjects: 49
Study 22578243 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactose malabsorption
Number of subjects: 220
Study 22578243 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose malabsorption
Number of subjects: 220
Study 22578243 — intervention group
Group type: EXPERIMENTAL
Intervention: Open provocation with lactose
Number of subjects: 220
Study 22578243 — intervention group
Group type: EXPERIMENTAL
Intervention: Open provocation with fructose
Number of subjects: 220
Study 22578243 — intervention group
Group type: COMPARATOR
Intervention: DBPC provocation with lactose
Number of subjects: 220
Study 22578243 — intervention group
Group type: COMPARATOR
Intervention: DBPC provocation with fructose
Number of subjects: 220
Study 20118387 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescription omega-3-acid ethyl esters plus atorvastatin (10 mg/d)
Number of subjects: 100
Study 20118387 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescription omega-3-acid ethyl esters plus atorvastatin (20 mg/d)
Number of subjects: 100
Study 20118387 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescription omega-3-acid ethyl esters plus atorvastatin (40 mg/d)
Number of subjects: 100
Study 20118387 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescription omega-3-acid ethyl esters plus atorvastatin
Number of subjects: 100
Study 20118387 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus atorvastatin
Number of subjects: 100
Study 18807572 — intervention group
Group type: EXPERIMENTAL
Intervention: Early placement of single-tooth implants (average 10 days after extraction)
Number of subjects: 45
Study 18807572 — intervention group
Group type: COMPARATOR
Intervention: Delayed placement of single-tooth implants (3 months after extraction)
Number of subjects: 45
Study 18807572 — intervention group
Group type: EXPERIMENTAL
Intervention: Early placement of single-tooth implants
Number of subjects: 45
Study 18807572 — intervention group
Group type: COMPARATOR
Intervention: Delayed placement of single-tooth implants
Number of subjects: 45
Study 18807572 — intervention group
Group type: EXPERIMENTAL
Intervention: Both early and delayed placement of single-tooth implants
Number of subjects: 45
Study 15477398 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 to 80 mg daily
Number of subjects: 27
Study 11323340 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 microg/kg fentanyl
Number of subjects: 150
Study 11323340 — intervention group
Group type: COMPARATOR
Intervention: Control (intranasal saline)
Number of subjects: 150
Study 11323340 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 microg/kg fentanyl
Number of subjects: 150
Study 9150584 — intervention group
Group type: EXPERIMENTAL
Intervention: High need for closure
Number of subjects: 0
Study 9150584 — intervention group
Group type: COMPARATOR
Intervention: Low need for closure
Number of subjects: 0